Acurx Pharmaceuticals, INC. (ACXP) — DEF 14A Filings
All DEF 14A filings from Acurx Pharmaceuticals, INC.. Browse 3 Proxy Statement reports with AI-powered summaries and risk analysis.
DEF 14A Filings (3)
-
Acurx Seeks Shareholder Nod for Warrant Issuance, Stock Increase
— Aug 4, 2025 Risk: high
Acurx Pharmaceuticals, Inc. (ACXP) is holding a special meeting on September 16, 2025, to address critical corporate governance and financing matters. The compa -
Acurx Seeks Reverse Stock Split Approval Amid Listing Concerns
— May 29, 2025 Risk: high
Acurx Pharmaceuticals, Inc. (ACXP) filed a DEF 14A on May 29, 2025, outlining proposals for its virtual Annual Meeting on July 17, 2025. Key proposals include t -
Acurx Pharmaceuticals, Inc. Announces 2024 Annual Meeting of Stockholders
— Apr 29, 2024 Risk: low
Acurx Pharmaceuticals, Inc. (ACXP) filed a Proxy Statement (DEF 14A) with the SEC on April 29, 2024. Acurx Pharmaceuticals, Inc. will hold its 2024 annual meeti
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX